Global energy prices now respond quickly to geopolitical events, which keeps pressure on healthcare systems to do more with constrained budgets and staff. That is where transformative AI healthcare stocks come in. These companies aim to cut costs and improve outcomes through smarter diagnostics, automation and virtual care. This article highlights three stocks from the Transformative AI Healthcare screener that show how this theme is playing out today.

The three stocks below are just a starting sample, and the full Transformative AI Healthcare screen surfaced 40 more companies with equally compelling stories that are not covered here. To identify potential fits for your own watchlist, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter and analyze the highest conviction plays in this theme.

Pfizer (PFE)

Pfizer is a global biopharmaceutical company that discovers, develops and sells medicines and vaccines across areas such as cardiovascular disease, oncology, rare diseases and infectious disease. Its Global Biopharmaceuticals Business generated about US$62.3b in revenue, with a smaller US$1.4b segment adjustment, underscoring how heavily it leans on its core drug and vaccine portfolio. The stock is a large cap with a market value of roughly US$152.5b.

Pfizer sits at the intersection of large scale pharma and AI powered drug development, with a deep late stage pipeline in oncology, rare disease and obesity that could reshape its earnings mix over time. Recent news around obesity drug Berobenatide, new cancer indications and updated vaccines shows how active the portfolio is. Analysts have noted that recent margins have come under pressure, while revenue is expected to decline for a few years and earnings are forecast to grow. High debt, a dividend that is not well covered by earnings, and upcoming patent expiries mean this is not a low risk story. However, the wide DCF discount and breadth of pipeline make Pfizer a stock many investors may wish to research in more detail.

Pfizer’s wide DCF discount and busy late stage pipeline are pulling in different directions. Get the full picture with the 2 key rewards and 4 important warning signs and see what might be hiding behind the headline story.

Build your own AI healthcare shortlist

Pfizer and the two other stocks in this list all came from a single AI healthcare screener, but the real value is creating your own set of rules. Use our flexible Screener to mix valuation, growth, balance sheet and risk filters in a way that fits you, or start with any of our curated Investing Ideas.

Medtronic (MDT)

Medtronic is a global medical device company that supplies pacemakers, heart valves, surgical tools, neuromodulation systems and AI powered surgical platforms to hospitals and clinicians. It generates the bulk of its roughly US$36.4b annual revenue from Cardiovascular at about US$14.0b, Neuroscience at about US$10.3b and Medical Surgical at about US$8.8b, with smaller contributions from Other and segment adjustments. The stock is a large cap with a market value of about US$111.6b.

Medtronic gives investors direct exposure to AI in the operating room through its Hugo robotic surgery system and Touch Surgery Aide guidance platform, alongside long established cardiac and neuromodulation franchises. The company offers a long dividend track record and broad device portfolio, yet faces execution risk related to multiple product recalls, margin pressure and the complex Diabetes spin off. For investors who want to understand whether this combination of AI driven projects and balance sheet risk is appropriate for their portfolio, the details behind Medtronic’s earnings forecasts, product pipeline and capital allocation approach may be more relevant than the headline P/E.

Medtronic’s AI surgery story and long dividend record can make the recent recalls and spin off plans easy to overlook. Read the full analysis report for Medtronic to see whether the real turning point is still ahead.

Hinge Health (HNGE)

Hinge Health runs a tech based platform for musculoskeletal care that uses AI motion tracking and a nerve stimulation wearable to support people with injuries, chronic pain and rehab, largely for self insured employers. All of its US$720.1 million in revenue comes from healthcare software, so the business is tightly focused on software driven care delivery. The stock has a market value of about US$7.2b.

Investors watching AI in healthcare may want Hinge Health on their radar because the company is pairing growth in digital MSK programs with expanding AI tools that aim to lift margins and clinician capacity. Management has been raising guidance, pushing into new areas such as gastrointestinal care through the Cylinder Health deal and discussing long term margin targets above 35%. The catch is that the stock trades on a high P/E, relies heavily on external funding and now needs to demonstrate it can integrate acquisitions while keeping growth and profitability on track.

Hinge Health’s fast growing digital MSK footprint and AI tools have many investors focused on the headline P/E. See how the analyst forecasts for Hinge Health reframes the story and why the real pivot point might not be what you expect.

Curious About Alternative Stock Paths?

Fresh stock themes can move from quiet to breakout before most investors even notice. Do not get caught chasing momentum after it is flying. Consider researching opportunities early instead of reacting later.

• Spot income opportunities that might hold up when growth stocks cool and review the 8 dividend fortresses while yields are still under the radar.
• Explore early stage AI candidates and scan the 71 profitable AI stocks that aren't just burning cash to find businesses that already pair algorithms with real earnings.
• Look into potential infrastructure-related ideas and review the 37 power grid technology and infrastructure stocks while these picks remain mostly overlooked by the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.